Experimental Support 1 for Functional miRNA-Target Interaction
miRNA:Target
hsa-miR-378c
-- Functional MTI --
KDM8
Validation Method
miRNA and mRNA specific interaction
Conditions
Flp-In T-REx 293-hAGO1 cells
Location of target site
CDS
Original Description (Extracted from the article)
...
Validation of interactions identified by CLASH suppports their reliability.
...
- Helwak A; Kudla G; Dudnakova T; Tollervey D, 2013,
Cell .
miRNA-target interactions (Provided by authors)
ID
Duplex structure
Position
1
miRNA 3' ggugagaagacugagguucaGGUCa 5'
||||
Target 5' ggcctgcccgtggctccctcCCAGa 3'
6 - 30
Article
- Helwak A; Kudla G; Dudnakova T; Tollervey D
- Cell , 2013
MicroRNAs (miRNAs) play key roles in gene regulation, but reliable bioinformatic or experimental identification of their targets remains difficult. To provide an unbiased view of human miRNA targets, we developed a technique for ligation and sequencing of miRNA-target RNA duplexes associated with human AGO1. Here, we report data sets of more than 18,000 high-confidence miRNA-mRNA interactions. The binding of most miRNAs includes the 5' seed region, but around 60% of seed interactions are noncanonical, containing bulged or mismatched nucleotides. Moreover, seed interactions are generally accompanied by specific, nonseed base pairing. 18% of miRNA-mRNA interactions involve the miRNA 3' end, with little evidence for 5' contacts, and some of these were functionally validated. Analyses of miRNA:mRNA base pairing showed that miRNA species systematically differ in their target RNA interactions, and strongly overrepresented motifs were found in the interaction sites of several miRNAs. We speculate that these affect the response of RISC to miRNA-target binding.
LinkOut: [ PMID: 23622248 ]
MiRNA-Target Expression Profile
Dataset
Pearson Correlation
P-value for Pearson Correlation
Spearman Correlation
P-value for Spearman Correlation
Samples
Chart
MiRNA-Target Expression Profile (TCGA)
Tumor
Pearson Correlation
P-value for Pearson Correlation
Spearman Correlation
P-value for Spearman Correlation
Samples
Chart
miRNA-Drug Resistance Associations
miRNA
Drug Name
CID
NSC
FDA
Effect/Pattern
Detection Method
Level
Phenotype
Condition
hsa-mir-378c
Tamoxifen
2733525
NSC180973
approved
resistant
High
Breast Cancer
cell line (MCF-7, T47D)
hsa-mir-378c
Cisplatin
5460033
NSC119875
approved
resistant
High
Gastric Cancer
cell line (BGC823)
hsa-miR-378c
Fluorouracil
3385
NSC19893
approved
resistant
High
Pancreatic Cancer
cell line (PANC-1)
hsa-miR-378c
Gemcitabine
60750
NSC613327
approved
resistant
High
Pancreatic Cancer
cell line (PANC-1)
hsa-miR-378c
Gemcitabine
60750
NSC613327
approved
resistant
High
Pancreatic Cancer
cell line (SW1990)
hsa-miR-378c
Gemcitabine
60750
NSC613327
approved
sensitive
High
Pancreatic Cancer
cell line (SW1990)
hsa-miR-378c
Cisplatin
5460033
NSC119875
approved
resistant
High
Ovarian Cancer
cell line (A2780)
hsa-miR-378c
Cisplatin
5460033
NSC119875
approved
resistant
High
Ovarian Cancer
cell line (A2780)
hsa-miR-378c
Aromatase Inhibitor
sensitive
Low
Breast Cancer
cell line (MCF-7)
hsa-miR-378c
Imatinib
5291
NSC743414
approved
resistant
High
Chronic Myelogenous Leukemia
tissue
hsa-miR-378c
Palbociclib
5330286
NSC758247
approved
sensitive
High
Breast Cancer
cell line (T47D)
hsa-miR-378c
Doxorubicin
31703
NSC123127
approved
resistant
High
Breast Cancer
tissue
hsa-miR-378c
Paclitaxel
36314
NSC125973
approved
resistant
High
Breast Cancer
tissue
hsa-mir-378c
Androstenedione
6128
NSC9563
sensitive
cell line (MCF-7)
hsa-mir-378c
Androstenedione+Anastrozole
sensitive
cell line (MCF-7)
hsa-mir-378c
Tamoxifen
2733525
NSC180973
approved
resistant
cell line (MCF7)
hsa-mir-378c
Cisplatin
5460033
NSC119875
approved
resistant
cell line (BGC-823)
hsa-miR-378c
Temozolomide
5394
NSC362856
approved
resistant
cell line (U251)
hsa-miR-378c
Palbociclib
5330286
NSC758247
approved
sensitive
tissue (breast cancer)
hsa-miR-378c
Cisplatin
5460033
NSC119875
approved
resistant
cell line (A549)
hsa-miR-378c
Doxorubicin
31703
NSC123127
approved
sensitive
cell line (BAS)
hsa-miR-378c
Cisplatin
5460033
NSC119875
approved
sensitive
cell line (A549)
hsa-miR-378c
Cisplatin
5460033
NSC119875
approved
sensitive
cell line (A2780)
hsa-miR-378c
Cisplatin
5460033
NSC119875
approved
sensitive
cell line (A549)
hsa-miR-378c
Gemcitabine
60750
NSC613327
approved
sensitive
cell line (PANC-1) (100 ng/ml)
hsa-miR-378c
Gemcitabine
60750
NSC613327
approved
sensitive
cell line (PANC-1) (1500 ng/ml)
hsa-miR-378c
Gemcitabine
60750
NSC613327
approved
resistant
cell line (Panc1-GR4)